SCHEMBL2005448

SCHEMBL2005448

CCc1ccc(S(=O)(=O)n2ccc3cc(OC)ccc32)cc1NCCN(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 13/20 0.53
POLB P06746 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HDAC1 Q13547 4/20 0.52
HDAC6 Q9UBN7 3/20 0.51
FABP4 P15090 1/20 0.46
HDAC3 O15379 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
HDAC4 P56524 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
PPARG P37231 2/20 0.43
PPARD Q03181 2/20 0.43
PPARA Q07869 2/20 0.43
HTR1A P08908 1/20 0.43
DRD2 P14416 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2008376 0.89 HTR6 (0.54) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL2010374 0.86 HTR6 (0.44) HTR6HDAC1HDAC6FABP4HDAC3
SCHEMBL2006309 0.86 HTR6 (0.46) HTR6HDAC1PPARGPPARDPPARA
SCHEMBL2005850 0.86 HTR6 (0.43) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL2009721 0.85 HTR6 (0.53) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL2010180 0.83 HTR6 (0.56) HTR6HTR1ADRD2HTR1DHTR1B
SCHEMBL1971893 0.82 HTR6 (0.54) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL1973557 0.81 HTR6 (0.53) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL2312698 0.79 HTR6 (0.50) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL2001031 0.77 PDE4A (0.47) HTR6POLBL3MBTL1HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200980-B9 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION SUVEN LIFE SCIENCES LTD (IN) 2011-12-28 EP claimed
EP-2200980-B1 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION SUVEN LIFE SCIENCES LTD (IN) 2011-08-03 EP claimed
US-7964627-B2 Amino arylsulfonamide compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2011-06-21 US claimed
US-20100216861-A1 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-08-26 US claimed
US-7964627-B2 Amino arylsulfonamide compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100216861-A1 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216861-A1 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS HTR6, HTR5A, HTR1A HTR6 1/4885POLB 4667/4885L3MBTL1 3618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.